Puma Biotechnology Net Worth
Puma Biotechnology Net Worth Breakdown | PBYI |
Puma Biotechnology Net Worth Analysis
Puma Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Puma Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Puma Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Puma Biotechnology's net worth analysis. One common approach is to calculate Puma Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Puma Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Puma Biotechnology's net worth. This approach calculates the present value of Puma Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Puma Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Puma Biotechnology's net worth. This involves comparing Puma Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Puma Biotechnology's net worth relative to its peers.
Enterprise Value |
|
To determine if Puma Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Puma Biotechnology's net worth research are outlined below:
| Puma Biotechnology had very high historical volatility over the last 90 days | |
| Puma Biotechnology has a strong financial position based on the latest SEC filings | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
Puma Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Puma Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Puma Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Puma Biotechnology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Puma Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Puma Biotechnology backward and forwards among themselves. Puma Biotechnology's institutional investor refers to the entity that pools money to purchase Puma Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kennedy Capital Management Inc | 2024-09-30 | 593 K | State Street Corp | 2024-06-30 | 514 K | Globeflex Capital, L.p. | 2024-09-30 | 452.6 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 354.5 K | Northern Trust Corp | 2024-09-30 | 317.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 309 K | Winton Capital Group Ltd | 2024-09-30 | 309 K | Sei Investments Co | 2024-06-30 | 289.5 K | Qube Research & Technologies | 2024-06-30 | 273.2 K | Vanguard Group Inc | 2024-09-30 | 3.6 M | Blackrock Inc | 2024-06-30 | 3.6 M |
Follow Puma Biotechnology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 148.24 M.Market Cap |
|
Project Puma Biotechnology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.25 | 0.26 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.40 | 0.42 |
When accessing Puma Biotechnology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Puma Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Puma Biotechnology's profitability and make more informed investment decisions.
Evaluate Puma Biotechnology's management efficiency
Puma Biotechnology has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4232 %, meaning that it created $0.4232 on every $100 dollars invested by stockholders. Puma Biotechnology's management efficiency ratios could be used to measure how well Puma Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. The Puma Biotechnology's current Return On Tangible Assets is estimated to increase to 0.13. The Puma Biotechnology's current Return On Capital Employed is estimated to increase to 0.26. As of now, Puma Biotechnology's Return On Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.13 | 2.22 | |
| Tangible Book Value Per Share | (0.16) | (0.15) | |
| Enterprise Value Over EBITDA | 4.86 | 5.10 | |
| Price Book Value Ratio | 3.82 | 3.63 | |
| Enterprise Value Multiple | 4.86 | 5.10 | |
| Price Fair Value | 3.82 | 3.63 | |
| Enterprise Value | 231 M | 219.4 M |
The strategic vision of Puma Biotechnology management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Enterprise Value Revenue 0.5621 | Revenue 243.6 M | Quarterly Revenue Growth 0.435 | Revenue Per Share 5.045 | Return On Equity 0.4232 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Puma Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Puma Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Puma Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Puma Biotechnology Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 27th of August 2024 Other Reports | ViewVerify |
Puma Biotechnology Earnings per Share Projection vs Actual
Puma Biotechnology Corporate Management
| Jeffrey Ludwig | Chief Officer | Profile | |
| Alvin Pharmd | Chief Officer | Profile | |
| FRAPS BSc | Pharmacovigilance, Affairs | Profile | |
| Bo Chao | Senior Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.